Literature DB >> 15300888

Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma.

Xiu-Jie Wang1, Shu-Lan Yuan, Qing Lu, Yan-Rong Lu, Jie Zhang, Yan Liu, Wen-Dong Wang.   

Abstract

AIM: To investigate the potential involvement of leptin in carcinogenesis of hepatocellular carcinoma (HCC) and to elucidate the etiology, carcinogenesis and progress of HCC.
METHODS: Expressions of Ob gene product, leptin and its receptor, Ob-R were investigated in 36 cases of HCC specimens and corresponding adjacent non-tumorous liver tissues with immunohistochemical staining. The effect of leptin on proliferation of Chang liver cell line and liver cancer cell line SMMC-7721 was studied with cell proliferation assay (MTT).
RESULTS: Leptin expression was detected in 36 cases of adjacent non-tumorous liver tissues (36/36, 100%) with moderate (++) to strong (+++) intensity; and in 72.22%(26/36) of HCC with weaker (+) intensity (P<0.05). Thirty of 36 (83.33%) cases of adjacent non-tumorous liver tissues were positive for Ob-R, with moderate (++) to strong (+++) intensity. In HCC, 11/36 (30.56%) cases were positive, with weak (+) intensity (P<0.05). In cell proliferation assay, leptin inhibited the proliferation of Chang liver cells. The cell survival rate was 10-13% lower than that of the untreated cells (P>0.05). Leptin had little effect on the proliferation of liver cancer cells (P>0.05).
CONCLUSION: High level expression and decreased or absent expression of leptin and its receptor in adjacent non-tumorous liver cells and HCC cells, inhibitory effect of leptin on the proliferation of normal Chang liver cells and no effect of leptin on proliferation of liver cancer cells, may provide new insights into the carcinogenesis and progression of human HCC. It could be assumed that leptin acting as an inhibitor and/or promoter, is involved in the process of carcinogenesis and progress of human HCC. Copyright 2004 The WJG Press ISSN

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300888      PMCID: PMC4572145          DOI: 10.3748/wjg.v10.i17.2478

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

1.  Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism.

Authors:  B Campillo; E Sherman; J P Richardet; P N Bories
Journal:  Eur J Clin Nutr       Date:  2001-11       Impact factor: 4.016

2.  Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?

Authors:  S Yang; H Z Lin; J Hwang; V P Chacko; A M Diehl
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Leptin and body mass index in relation to endometrial cancer risk.

Authors:  Eleni Petridou; Maria Belechri; Nick Dessypris; Panagiotis Koukoulomatis; Emmanuel Diakomanolis; Evangelos Spanos; Dimitrios Trichopoulos
Journal:  Ann Nutr Metab       Date:  2002       Impact factor: 3.374

4.  Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms.

Authors:  Ponnandai Somasundar; Dale Riggs; Barbara Jackson; Linda Vona-Davis; David W McFadden
Journal:  Am J Surg       Date:  2003-11       Impact factor: 2.565

5.  Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line.

Authors:  Stefania Catalano; Stefania Marsico; Cinzia Giordano; Loredana Mauro; Pietro Rizza; Maria Luisa Panno; Sebastiano Andò
Journal:  J Biol Chem       Date:  2003-05-06       Impact factor: 5.157

6.  Serum leptin levels in patients with liver cirrhosis and chronic viral hepatitis.

Authors:  A Comlekci; H Akpinar; S Yesil; I Okan; E Ellidokuz; A Okan; G Ersoz; E Tankurt; Y Batur
Journal:  Scand J Gastroenterol       Date:  2003-07       Impact factor: 2.423

7.  Significance of leptin expression in invasive potential of pituitary adenomas.

Authors:  Mitsuo Isono; Ryo Inoue; Tohru Kamida; Hidenori Kobayashi; Junko Matsuyama
Journal:  Clin Neurol Neurosurg       Date:  2003-04       Impact factor: 1.876

8.  Leptin in relation to hepatocellular carcinoma in patients with liver cirrhosis.

Authors:  Ya-Yu Wang; Shih-Yi Lin
Journal:  Horm Res       Date:  2003

9.  Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden.

Authors:  Pär Stattin; Richard Palmqvist; Stefan Söderberg; Carine Biessy; Bjarne Ardnor; Göran Hallmans; Rudolf Kaaks; Tommy Olsson
Journal:  Oncol Rep       Date:  2003 Nov-Dec       Impact factor: 3.906

Review 10.  The role of leptin in human physiology and pathophysiology.

Authors:  R Janeckova
Journal:  Physiol Res       Date:  2001       Impact factor: 1.881

View more
  14 in total

1.  Potential role of leptin expression in hepatocellular carcinoma.

Authors:  S-N Wang; Y-T Yeh; S-F Yang; C-Y Chai; K-T Lee
Journal:  J Clin Pathol       Date:  2006-03-24       Impact factor: 3.411

Review 2.  Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma.

Authors:  Asma Siddique; Kris V Kowdley
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

Review 3.  Leptin in hepatocellular carcinoma.

Authors:  Shen-Nien Wang; King-Teh Lee; Chen-Guo Ker
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

4.  Leptin enhances cholangiocarcinoma cell growth.

Authors:  Giammarco Fava; Gianfranco Alpini; Chiara Rychlicki; Stefania Saccomanno; Sharon DeMorrow; Luciano Trozzi; Cinzia Candelaresi; Julie Venter; Antonio Di Sario; Marco Marzioni; Italo Bearzi; Shannon Glaser; Domenico Alvaro; Luca Marucci; Heather Francis; Gianluca Svegliati-Baroni; Antonio Benedetti
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

5.  Primary study of leptin and human hepatocellular carcinoma in vitro.

Authors:  Jing Zhou; Wei Lei; Lei Shen; He-Sheng Luo; Zhi-Xiang Shen
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

6.  Impact of obesity on the surgical outcome following repeat hepatic resection in Japanese patients with recurrent hepatocellular carcinoma.

Authors:  Tohru Utsunomiya; Masahiro Okamoto; Toshihumi Kameyama; Ayumi Matsuyama; Manabu Yamamoto; Megumu Fujiwara; Masaki Mori; Shiomi Aimitsu; Teruyoshi Ishida
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

7.  Hepatoma cell-derived leptin downregulates the immunosuppressive function of regulatory T-cells to enhance the anti-tumor activity of CD8+ T-cells.

Authors:  Renxiong Wei; Yaoren Hu; Feibo Dong; Xiaozhen Xu; Airong Hu; Guosheng Gao
Journal:  Immunol Cell Biol       Date:  2015-12-07       Impact factor: 5.126

8.  Potential prognostic value of leptin receptor in hepatocellular carcinoma.

Authors:  S-N Wang; S-C Chuang; Y-T Yeh; S-F Yang; C-Y Chai; W-T Chen; K-K Kuo; J-S Chen; K-T Lee
Journal:  J Clin Pathol       Date:  2006-03-24       Impact factor: 3.411

9.  Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment.

Authors:  Naoki Watanabe; Koji Takai; Kenji Imai; Masahito Shimizu; Takafumi Naiki; Masahito Nagaki; Hisataka Moriwaki
Journal:  J Clin Biochem Nutr       Date:  2011-10-29       Impact factor: 3.114

Review 10.  Leptin signaling molecular actions and drug target in hepatocellular carcinoma.

Authors:  Nan Jiang; Rongtong Sun; Qing Sun
Journal:  Drug Des Devel Ther       Date:  2014-11-14       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.